A study to determine whether a single hormone injection a month before insertion of the contraceptive implant will reduce or stop irregular vaginal bleeding

ISRCTN ISRCTN45049889
DOI https://doi.org/10.1186/ISRCTN45049889
Secondary identifying numbers 10467
Submission date
13/05/2008
Registration date
07/08/2008
Last edited
09/05/2016
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Urological and Genital Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Sharon Moses
Scientific

Bristol Sexual Health Centre
Tower Hill
Bristol
BS2 0JD
United Kingdom

Study information

Study designSingle-centre, single-blind randomised placebo-controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Not specified
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleIrregular vaginal bleeding with etonorgestrel contraceptive implant: a pilot randomised controlled trial of prophylactic down regulation with a gonadotrophin releasing hormone analogue prior to implant insertion
Study objectivesImplanon® is the only progesterone-only sub-dermal contraceptive implant available in the United Kingdom (UK). It is independent of compliance, lasts for three years and has been shown to be effective, safe and easily reversible. UK data suggests almost two thirds of women who discontinue Implanon® do so for frequent or unpredictable bleeding, interventions to improve bleeding patterns are likely to have an effect of increasing continuation rates.

Gonadotrophin releasing hormone agonists (GnRHa) are a group of drugs with an agonist/antagonist action on the GnRH receptor in the pituitary gland. They induce down regulation of the pituitary resulting in blockage of gonadotrophin synthesis and secretion. GnRHa produce inhibition of pituitary function, follicular development, anovulation and a reversible hypogonadotrophic hypogonadism state which frequently induces amenorrhoea. What is uncertain is whether these effects are prolonged following the administration of progestagens.

It is therefore hypothesised that the amenorrhoea associated with down regulation by GnRHa one month prior to fitting Implanon® will persist after insertion, with a resultant high continuation rate and quality of life.
Ethics approval(s)Ethics approval received from the Leicestershire, Northamptonshire and Rutland Research Ethics Committee 2 on the 1st May 2008 (ref: 08/H0402/3).
Health condition(s) or problem(s) studiedContraception, vaginal bleeding
InterventionGnRH analogue and placebo:
1. Decapeptyl SR®, contains the active ingredient triptorelin acetate which is a gonadorelin analogue. The dose of the intramuscular injection is 11.25 mg, which is a sustained release preparation lasting for 90 days. It comes in a pre-filled syringe which will be supplied by the manufacturer in its standard form.
2. Placebo injection will consist of a 5 ml intramuscular injection of water for injection in its standard form

The treatment is a one off injection of either Decapeptyl SR or placebo and then a month later the implant is fitted and the women are followed up for one year (both treatment arms) so involvement for the women is 13 months.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Specified
Drug / device / biological / vaccine name(s)Decapeptyl SR®
Primary outcome measureMean number of bleeding and spotting days over each 90 day reference period for a total of one year from contraceptive implant insertion.
Secondary outcome measures1. World Health Organisation (WHO) menstrual indices:
1.1. Number of vaginal bleeding and spotting episodes
1.2. Length of bleeding and spotting episodes
1.3. Length of bleeding and spotting free intervals
1.4. Range of bleeding and spotting free intervals
2. Continuation rates of the contraceptive implant at 12 months
3. Quality of life assessment with further 36-item Short Form health survey (SF-36) scores at 12 months
Overall study start date01/07/2008
Completion date31/12/2009

Eligibility

Participant type(s)Patient
Age groupAdult
SexFemale
Target number of participants90
Key inclusion criteria1. Women aged 20 - 40 years
2. Requesting Implanon® for contraception after appropriate counselling and consent
3. Willing to follow study protocol
4. Informed consent to participate in study
Key exclusion criteria1. Contraindications to Implanon®:
1.1. Pregnancy
1.2. Undiagnosed vaginal bleeding
1.3. Severe arterial disease
1.4. Liver adenoma
1.5. Porphyria
1.6. Active gestational trophoblastic disease
1.7. Sex-steroid dependent cancer
1.8. Enzyme inducing medication
2. Contraindications to GnRHa:
2.1. Pregnancy
2.2. Undiagnosed vaginal bleeding
2.3. Breastfeeding
2.4. Metabolic bone disease
3. Unwilling to keep a regular menstrual diary
4. Unwilling to follow study protocol
5. Unable to understand patient information leaflet
6. Current involvement in other research projects
7. Within six weeks of termination of pregnancy
Date of first enrolment01/07/2008
Date of final enrolment31/12/2009

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

Contraceptive Services
Leicester
LE2 0TA
United Kingdom

Sponsor information

University Hospitals of Leicester NHS Trust (UK)
Hospital/treatment centre

c/o David Rowbotham
Research Office
Leicester General Hospital
Gwendolen Road
Leicester
LE5 4PW
England
United Kingdom

Website http://www.uhl-tr.nhs.uk/
ROR logo "ROR" https://ror.org/02fha3693

Funders

Funder type

Other

Investigator initiated and funded (UK)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Editorial Notes

09/05/2016: No publications found, verifying study status with principal investigator.